Metabolic dysfunction–associated steatohepatitis (MASH) is the new term that replaces nonalcoholic steatohepatitis (NASH), developed by multinational liver societies, including the American Association for the Study of Liver Diseases (AASLD). A recently validated model presented at the AASLD Liver Meeting 2023 predicted a steady increase in the prevalence of metabolic dysfunction–associated steatotic liver disease (MASLD) among adults, from 27.8% in 2020 to 34.3% by 2050. Worldwide, MASLD and MASH are most prevalent in the Middle East and North Africa, followed by South Asia and North America, but these liver diseases remain global problems. Are you aware of the latest MASH diagnostic criteria for managing and treating patients? Test yourself with this short quiz.

Source: The North Africa Journal January 19, 2024 21:24 UTC